[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334954-105":59,"doc-detail-334954-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","population-based-study-on-the-progress-in-survival-of-primarily-metastatic-lung-cancer-patients-in-germany","Population based study - on the progress in survival of primarily metastatic lung cancer patients in Germany","","Study assesses how new treatment strategies affect survival among primarily metastatic lung cancer patients in Germany and compares outcomes between non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Population-based registry data from the Robert-Koch Institute covering diagnoses from 2007–2018 were analyzed using Kaplan–Meier survival curves and multivariable hazard ratios. Overall survival showed a moderate increase over time. Chemotherapy increased survival for all patients; radiotherapy benefited SCLC but not NSCLC, while NSCLC immunotherapy improved survival.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/population-based-study-on-the-progress-in-survival-of-primarily-metastatic-lung-cancer-patients-in-germany/334954/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/population-based-study-on-the-progress-in-survival-of-primarily-metastatic-lung-cancer-patients-in-germany/334954.png","ImageObject",300,407,{"name":92,"@type":93},"Maeve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of the population-based study?","Question",{"text":112,"@type":113},"To evaluate the impact of new lung cancer treatment strategies on survival over time in primarily metastatic patients and to compare outcomes between NSCLC and SCLC.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which data source and patient timeframe were used?",{"text":117,"@type":113},"The study used population-based data from the Robert-Koch Institute (RKI), including patients diagnosed between 2007 and 2018.",{"name":119,"@type":110,"acceptedAnswer":120},"How did survival change over time and with specific therapies?",{"text":121,"@type":113},"Survival increased moderately over time. Chemotherapy increased survival for all patients; radiotherapy mainly benefited SCLC, while NSCLC immunotherapy increased survival as well.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334954,1790458061,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},5909877438554,"https://ap-avatar.wpscdn.com/avatar/5600025385ad2bf12a7?_k=1778553567797529272","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nPopulation based study  \non the progress in survival of primarily metastatic lung cancer patients in Germany  \nTherese Tzschoppe1, Julia Ohlinger1, Dirk Vordermark1, Ahmed Bedir1,2 &  \nDaniel Medenwald1,2*  \nLung cancer is known for its high mortality; many patients already present with metastases atthe time of diagnosis. The aim of this study is to assess the impact of new treatment strategies on the survival of primarily metastatic lung cancer patients and to analyze the differences in outcomes between non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) patients. Populationbased data, provided by the Robert-Koch Institute in Germany, was used and patients diagnosed between 2007 and 2018 were included in the study. We differentiated between NSCLC and SCLC patients and analyzed the survival over time for both sexes separately, using the Kaplan–Meier method. To evaluate survival advantages, we calculated multivariable hazard ratios. In total, 127,723 patients were considered for the study. We observed a moderate increase in survival over time. All patients showed an increased survival rate when undergoing chemotherapy. Minimal to no increase in survival was shown in NSCLC patients when receiving radiotherapy, whereas SCLC patients’ survival time did benefit from it. NSCLC patients receiving immunotherapy showed an increase in survival as well. It can be concluded that advancements in radiotherapy, the application of chemotherapy, and the introduction of immunotherapies lead to an increased survival time of both NSCLC and SCLC primarily metastatic lung cancer patients.  \nKeywords Lung cancer, Germany, Cancer registry, Survival  \nLung cancer is the second most commonly diagnosed malignant neoplasm worldwide and the leading cause of cancer mortality1. In 2020 an estimated 1.8 million patients died of lung cancer worldwide1.  \nAmong the many factors contributing to its high mortality, the lack of early symptoms and insufficient screening methods are two major reasons why most cases are not diagnosed until a later stage2. In Germany, over 50% of lung cancer cases are not diagnosed until reaching UICC-stage IV (Union for International Cancer Control)2. At this stage, the cancer has already metastasized into the contralateral lung or into at least one other organ, resulting in an unfavorable prognosis3: in 2016, the 5-year survival rate of primarily metastatic patients was estimated to be approximately 5%4. Hence, there is a need for reliable and innovative therapies, especially for this affected group of patients.  \nIn the past 20 years, new approaches have emerged and therapy plans have drastically changed, resulting inan increased life expectancy and an improved quality of life2.  \nThis downward trend of mortality has also been shown in epidemiological studies in Europe5.  \nToday, personalized medicine leads the way into the future of cancer therapy. This is especially important for patients with primarily metastatic lung cancer, who are the primary beneficiaries of immunotherapy and targeted therapies. In non-small cell lung cancer (NSCLC) patients diagnosed with stage IV cancer, an increase of up to four years of survival time can be expected6.  \nFurthermore, technological advances in radiotherapy have not only led to a reduction of incidental irradiation of surrounding healthy tissue but also enabled more precise targeting of tumors7. This has improved outcomes both in reducing toxicity and in increasing the survival rates of lung cancer patients7.  \n1 Department of Radiation Oncology, Health Services Research Group, University Hospital Halle (Saale), Ernst-Grube-Str. 40, 06120 Halle (Saale), Germany. 2These authors jointly supervised this work: Ahmed Bedir and Daniel Medenwald. *email: daniel. medenwald@uk-halle.de  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nThese and other new therapies continue to ","cbCaidLtNzyuyUPU","https://ap.wps.com/l/cbCaidLtNzyuyUPU","pdf",1177256,"English","# Introduction\n## Rationale and background\n# Methods\n## Data source and patient information\n## Survival analysis approach\n# Results\n## Survival trends and treatment effects\n# Discussion\n## Interpretation of treatment advancements","[{\"question\":\"What is the main goal of the population-based study?\",\"answer\":\"To evaluate the impact of new lung cancer treatment strategies on survival over time in primarily metastatic patients and to compare outcomes between NSCLC and SCLC.\"},{\"question\":\"Which data source and patient timeframe were used?\",\"answer\":\"The study used population-based data from the Robert-Koch Institute (RKI), including patients diagnosed between 2007 and 2018.\"},{\"question\":\"How did survival change over time and with specific therapies?\",\"answer\":\"Survival increased moderately over time. Chemotherapy increased survival for all patients; radiotherapy mainly benefited SCLC, while NSCLC immunotherapy increased survival as well.\"}]","Population based study - on the progress in survival of primarily metastatic lung cancer patients in Germany | PDF",1790009004,25]